Site Search

Assay Development

The overarching goal for Assay Development focuses on the timely delivery of robust and well validated assays to uHTS. Over the last 12 months, the Assay Development group has worked on more than 50 assays from 29 PI’s outside of the MLSCN Center of which 13 were also outside of the Scripps Research Institute. 23 assays were successfully transferred to uHTS. The breadth of our assay development production competency and the extent of our Outreach efforts to other institutions on behalf of MLSCN is demonstrated by the range of target classes and assay platforms shown below:

Funding Opportunities

News Articles

Online

We have 4 guests online

MS Drug Discovered at TSRI is Safe and Effective
in Phase II Study

A compound discovered
and synthesized in The Scripps Research Institute (TSRI) labs of
Professors Hugh Rosen and Edward Roberts has provided positive
results for safety and efficacy in Phase 2 clinical trials for
relapsing multiple sclerosis, according to Receptos, the
biopharmaceutical company developing the drug for approval by the
US Food and Drug Administration.

“The Rosen and Roberts
laboratories are very gratified to see these direct improvements in
the lives of patients and families dealing with this debilitating
illness,” said Rosen. “These data support our labs' approach at
TSRI—that discovery of fundamental mechanisms in chemical biology
provides the foundation for intelligent intervention in disease
processes. Meeting the needs of patients and their families is our
high calling in biomedical science.”

The drug candidate,
RPC1063, was first discovered at TSRI from work in the National
Institutes of Health (NIH) Molecular Libraries Initiative. The
randomized, double-blind Phase 2 study assessed the efficacy,
safety and tolerability of two orally administered doses of RPC1063
against placebo in 258 patients with relapsing multiple sclerosis
across 77 sites in 13 countries. There was a highly statistically
significant 86 percent reduction in MRI measures of disease
activity.